Skip to main content
SpringerLink
Log in

Nefiracetam

DM 9384, DZL 221, Translon

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Notes

  1. This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

References

  1. Fujimaki Y, Sudo K, Hakusui H, Tachizawa H, Murasaki M. Single- and multiple-dose pharmacokinetics of nefiracetam, a new nootropic agent, in healthy volunteers. J Pharm Pharmacol 44: 750–754, Sep 1992

    Article  PubMed  CAS  Google Scholar 

  2. Fujimaki Y, Sudo K, Hakusui H. Pharmacokinetics of nefiracetam and 3 metabolites in humans and stereoselective hydroxylation of its pyrrolidine ring. Xenobiotica 23: 61–70, Jan 1993

    Article  PubMed  CAS  Google Scholar 

  3. Kobayashi T, Ikeda M, Orishige T, Arai M, Ozawa H, et al. Investigation of DM-9384 (nefiracetam) in a long-term treatment of patients with after-effect of cerebrovascular disorders. Yakuri to Chiryo 22: 3645–3659, Aug 1994

    Google Scholar 

  4. Hasegawa T, Shigeno K, Hirata Y, Sato Y, Saso S, et al. Clinical evaluation of DM-9384 (nefiracetam) in a long-term treatment of patients with sequela of cerebrovascular disorders. Rinsho Iyaku 10: 2087–2106, No. 9, 1994

    Google Scholar 

  5. Ohtomo E, Kogure K, Hirai S, Goto F, Hasegawa K, et al. Clinical utility of DM-9384 (nefiracetam) in patients with aftereffect following cerebrovascular disorders: a comparative double-blind study with idebenone. Rinsho Iyaku 10: 1871–1918, No. 8, 1994

    Google Scholar 

  6. Ohtomo E, Kogure K, Hirai S, Goto F, Hasegawa K, et al. Clinical utility of DM-9384 (Nefiracetam) in the treatment of cerebrovascular disorders: dose finding study by double-blind method. Rinsho Iyaku 10: 1507–1547, No. 7, 1994

    Google Scholar 

  7. Goa KL, Benfield P. Nefiracetam. CNS Drugs. 6: 331–337, Oct 1996

    Article  CAS  Google Scholar 

  8. Watabe S, Yamaguchi H, Ashida S. Effect of DM-9384, a new cognition-enhancing agent, on GABA and cholinergic systems in rat cortex. Jpn J Pharmacol (Suppl 1): 294, 1990

    Google Scholar 

  9. Nabeshima T, Noda Y, Tohyama K, et al. Effects of DM-9384 in a model of amnesia based on animals with GABAergic neuronal dysfunctions. Eur J Pharmacol 178: 143–149, 20 Mar 1990

    Article  PubMed  CAS  Google Scholar 

  10. Kawajira S, Taniguchi K, Sakurai T, et al. Effect of DM-9384 on extracellular acetylcholine in the rat frontal cortex measured with microdialysis. Eur J Pharmacol 183: 928, Jul 1990

    Article  Google Scholar 

  11. Murai S, Saito H, Abe E, et al. Effect of acute and subchronic administration of DM-9384 and some cognition enhancers on the monoaminergic systems in certain regions of the mouse brain. Jpn J Pharmacol 55 (Suppl 1): 204, 1991

    Google Scholar 

  12. Abe E, Murai S, Saito H, et al. Effects of nefiracetam, a novel pyrrolidone derivative, on brain monoamine metabolisms in mice. J Neural Transm — Gen Sect 90: 125–136, No. 2, 1992

    Article  PubMed  CAS  Google Scholar 

  13. Murashima YL, Shinozaki T, Watabe S, Yoshii M. Regulation of cAMP by nefiracetam (DM-9384), a nootropic agent, through G-proteins in NG108-15 cells. Fourth IBRO World Congress of Neuroscience: 138, 9 Jul 1995

    Google Scholar 

  14. Yoshii M, Watabe S, Murashima YL, Shiotani T, Tanaka M. Enhancement of cAMP and inhibition of calcium signaling pathways by the nootropic agent nefiracetam (DM-9384) in NG108-15 cells. Fourth IBRO World Congress of Neuroscience: 125, 9 Jul 1995

    Google Scholar 

  15. Sakurai T, Hatanaka S, Tanaka S, et al. Protective effect ofDM- 9384, a novel pyrrolidine derivative, against experimental cerebral anoxia. Jpn J Pharmacol 54: 33–43, Sep 1990

    Article  PubMed  CAS  Google Scholar 

  16. Nabeshima T, Tohyama K, Murase K, et al. Effects ofDM-9384, a cyclic derivative of GABA, on amnesia and decreases in GABAA and Muscarinic receptors induced by cycloheximide. J Pharmacol Exp Ther 257: 271–275, Apr 1991

    PubMed  CAS  Google Scholar 

  17. Shiotani T, Tohyama K, Murase K, et al. Effects of nefiracetam, DM-9384 on amnesia and decrease in cholineacetyltransferase activity induced by cycloheximide. Journal of Neural Transmission — General Section. 90: 103–111, No. 2, 1992

    Article  PubMed  CAS  Google Scholar 

  18. Hiramatsu M, Koide T, Ishihara S-i, Shiotani T, Kameyama T, et al. Involvement of the cholinergic system in the effects of nefiracetam (DM-9384) on carbon monoxide (CO)-induced acute and delayed amnesia. Eur J Pharmacol 216: 279–285, 5 Jun 1992

    Article  PubMed  CAS  Google Scholar 

  19. Tanaka S, Shirasaki Y, Yamada F, et al. Impairment effect of DM-9384, a new cognition enhancer, on learning deficits in cerebral embolized rats. Jpn J Pharmacol 52 (Suppl 1): 74, 1990

    Google Scholar 

  20. Woodruff-Pak D. Nefiracetam. CNS Drugs. 6: Oct 1996

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nefiracetam. Drugs R&D 3, 212–216 (2002). https://doi.org/10.2165/00126839-200203030-00017

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200203030-00017

Keywords

Search

Navigation